E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute-on-chronic liver failure (ACLF) |
|
E.1.1.1 | Medical condition in easily understood language |
Acute-on-chronic liver failure (ACLF) |
|
E.1.1.2 | Therapeutic area | Not possible to specify |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10068752 |
E.1.2 | Term | Acute on chronic hepatic failure |
E.1.2 | System Organ Class | 100000004871 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
From the clinical point of view, overall survival and transplant-free survival are the most relevant outcome measures. Thus, the primary endpoint of the study is transplant-free survival up to 90 days, with death and liver transplantation (OLT) counting as event |
|
E.2.2 | Secondary objectives of the trial |
Beside overall survival and transplant-free survival time until the end of follow-up (see above) the following secondary endpoints will be evaluated:
• Complications of ACLF (hepatorenal syndrome (HRS), variceal bleeding, ascites, hepatic encephalopathy (HE)) within 90 days/within 360 days.
• Infections within 90 days/within 360 days (proven infection necessitating systemic use of antibiotics)
• Liver function during the course of treatment and follow-up (MELD-Score, Child-Pugh-Score)
• Duration of the initial hospital stay
These further secondary endpoints have been chosen in order to better understand the impact of G-CSF administration on liver function and on the development of complications during the course of ACLF, especially the rate of infectious complications. The time frame 90 days reflects the treatment of the initial ACLF event, while 360 days analysis reflects long-term effects
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Acute-on-chronic liver failure (ACLF) according to the consensus criteria recently defined by the CANONIC study group [Moreau 2013]. Patients with acute decompensation of cirrhosis [defined as acute development of one or more of the following: ascites (onset and/or worsening), hepatic encephalopathy (onset and/or worsening), gastrointestinal haemorrhage, bacterial infection] are classified as ACLF if one of the following applies:
• single kidney failure (serum creatinine level ≥ 2 mg/dl) or
• single failure of one of the following organ systems: liver, coagulation, circulation, or respiration,
together with
a serum creatinine level ranging from 1.5 to < 2.0 mg/dl and/or mild to moderate hepatic encephalopathy or
• single cerebral failure together with serum creatinine level ranging from 1.5 to < 2.0 mg/dl or
• two or more organ failures.
Organ failures are defined according to the CLIF-C OFs [Jalan 2014].
2. Age ≥ 18 years, male or female
3. Written informed consent |
|
E.4 | Principal exclusion criteria |
1. Prior not curatively treated or active malignancies
2. Sickle cell disease
3. Septic shock, defined by the following symptom complex: bacteraemia AND SIRS AND shock
4. WBC-count of > 50 x 109/L
5. Known HIV infection
6. Known intolerance to filgrastim
7. Suspected lack of compliance
8. Pregnant or nursing women
9. Fertile women (within two years of their last menstruation) without appropriate contraceptive measures (implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy) while participating in the trial (participants using a hormone-based method have to be informed of possible effects from the trial medication on contraception).
10. Participation in other interventional trials
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Transplant-free survival at 90 days, defined as time from randomization to death or OLT, censoring patients alive without OLT at the date of last information. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Overall survival at 360 days, defined as time from randomization to death, censoring patients alive at the date of last information (independent from an OLT done or not).
• Transplant-free survival at 360 days
• Complications of ACLF within 90 days/within 360 days. For each patient, every complication will be recorded including onset, HRS type 1/2, classification of ascites, and/or HE grade.
• Infections within 90 days/within 360 days necessitating systemic use of antibiotics
Complication (by highest scoring if applicable)/infections will be analysed per period of analysis regarding occurrence and number of episodes (if episodes delimitable)
• Liver function during the course of treatment and follow-up
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
standard therapy without G-CSF |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 17 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |